Oncoloxía médica

2017

1. A PAM50-based chemoendocrine score for hormone receptor-positive breast cancer with an intermediate risk of relapse

   Clinical Cancer Research, Vol. 23, Núm. 12, pp. 3035-3044

2. A Prospective Observational Study for Assessment and Outcome Association of Circulating Endothelial Cells in Clear Cell Renal Cell Carcinoma Patients Who Show Initial Benefit from First-line Treatment. The CIRCLES (CIRCuLating Endothelial cellS) Study (SOGUG-CEC-2011-01)

   European Urology Focus, Vol. 3, Núm. 4-5, pp. 430-436

3. A consensus statement on the gender perspective in lung cancer

   Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 527-535

4. A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)

   Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 616-624

5. A high-resolution map of transcriptional repression

   eLife, Vol. 6

6. A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study

   Oncotarget, Vol. 8, Núm. 42, pp. 73144-73153

7. A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN)

   Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 28, Núm. 7, pp. 1517-1522

8. An assessment of morphometric characteristics of the greater palatine canal using cone beam computed tomography

   Computed Tomography: Advances in Research and Applications (Nova Science Publishers, Inc.), pp. 67-87

9. Anatomical variations of the greater palatine canal in cone-beam computed tomography

   Surgical and Radiologic Anatomy, Vol. 39, Núm. 7, pp. 717-723

10. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: A multi-institution correlative biomarker study

    Annals of Oncology, Vol. 28, Núm. 7, pp. 1-9

11. Anti-PD-1/PD-L1-induced psoriasis from an oncological perspective

    Journal of the European Academy of Dermatology and Venereology

12. Anti-folate receptor-α IgE but not IgG recruits macrophages to attack tumors via TNFa/MCP-1 signaling

    Cancer Research, Vol. 77, Núm. 5, pp. 1127-1141

13. Assessment of HER2 status in resected gastric cancer in European population

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 28, pp. iii15

14. Bioética y oncología: una puerta abierta a la oportunidad

    Sociedad Oncológica de Galicia

15. Breast cancer chemoprevention: What and when?

    Cancer and Chemotherapy Reviews, Vol. 12, Núm. 2, pp. 46-57

16. Chromatin remodelling and DNA repair genes are frequently mutated in endometrioid endometrial carcinoma

    International Journal of Cancer, Vol. 140, Núm. 7, pp. 1551-1563

17. Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor receptor tyrosine kinase inhibitors: The necessity of repeated molecular analysis

    Translational Lung Cancer Research, Vol. 6, pp. S21-S34

18. Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain

    Clinical and Translational Oncology, Vol. 19, Núm. 6, pp. 667-681

19. Development of de novo psoriasis during nivolumab therapy for metastatic renal cell carcinoma: immunohistochemical analyses and clinical outcome

    APMIS

20. Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature

    Lung Cancer, Vol. 108, pp. 217-221